- Bleeding events in association with increases in prothrombin time have been reported in arthritis patients (mainly elderly) receiving celecoxib concurrently with warfarin, some of them fatal (see section 4.4).
- The current yield curve has led to very rapid increases in time deposits and to a substantial decline in annual M1 growth.
- A variable but limited decrease in red blood cell
- Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.
- Namely, extension in time, increase in the budget by up to 20%, a combination of these two, or tightening up of eligibility conditions.
- (1)Namely, extension in time, increase in the budget by up to 20%, a combination of these two, or tightening up of eligibility conditions.
- The current structure of yields has triggered substitution both within and into the broad monetary aggregate M3, leading to a pronounced decline in annual M1 growth and very rapid increases in time deposits.
- related parameters was observed, together with increases in activated partial thromboplastin time.
|
- Bleeding events in association with increases in prothrombin time have been reported in arthritis patients (mainly elderly) receiving celecoxib concurrently with warfarin, some of them fatal (see section 4.4).
- related parameters was observed, together with increases in activated partial thromboplastin time.
- A variable but limited decrease in red blood cell
- The current yield curve has led to very rapid increases in time deposits and to a substantial decline in annual M1 growth.
- The current structure of yields has triggered substitution both within and into the broad monetary aggregate M3, leading to a pronounced decline in annual M1 growth and very rapid increases in time deposits.
- Namely, extension in time, increase in the budget by up to 20%, a combination of these two, or tightening up of eligibility conditions.
- (1)Namely, extension in time, increase in the budget by up to 20%, a combination of these two, or tightening up of eligibility conditions.
- Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.
|